Supplements and Compounds Library
Every article, presentation, spotlight, and news item we've tagged to Supplements and Compounds.
Showing 73–96 of 328
Targeting Hyperoxia‐Induced Cellular Senescence in Developing Human Airway Cells: Senomorphics Versus Senolytics Versus Antioxidants
Moderate hyperoxia induces cellular senescence in developing airway tissue, with lasting consequences for lung function. Three mechanistically distinct interventions—Fucoidan, Dasatinib plus Quercetin, and MitoQ—each mitigate senescence through different pathways, offering potential strategies to prevent hyperoxia-related lung disease in premature infants.
Multi-system drug enhances weight loss beyond appetite control
AT7687, an experimental compound, demonstrated safety and target engagement across multiple organ systems in Phase 1 testing, with preclinical data suggesting enhanced weight loss when combined with existing obesity therapeutics. The dual-mechanism approach addresses both metabolic dysfunction and body composition simultaneously.
Frailty phenotype reveals heterogeneity in aging and distinct taurine associations
Aging presents distinct phenotypic pathways with different metabolic signatures, particularly involving taurine metabolism. Identifying these heterogeneous frailty patterns enables targeted intervention strategies rather than one-size-fits-all approaches to age-related decline.
New longevity drug SRN-901 shows 33% lifespan boost
SRN-901, a five-component oral combination therapy, demonstrated a 33% increase in median lifespan and 70% reduction in frailty progression in mice, with preserved physical function and reduced tumor incidence. The multi-pathway approach contrasts with single-target interventions, suggesting that aging requires simultaneous modulation of interconnected biological processes rather than isolated molecular manipulation.
GNC adds MitoQ Pure and MitoQ NAD to The Drop
GNC has introduced MitoQ Pure and MitoQ NAD+ Dual Action supplements targeting mitochondrial function and oxidative stress reduction. Both formulations address energy production and cellular aging through distinct mechanisms—direct antioxidant support and NAD+ level optimization.
Seragon study shows SRN-901 extends median lifespan in mice
SRN-901, an oral combinatorial drug, extended median remaining lifespan by 33% in aged mice on a Western diet, with a 46% reduction in hazard of death and 70% attenuation of frailty progression. Multi-omics analysis indicated upregulation of DNA repair and metabolic pathways alongside suppression of inflammatory and oxidative stress responses.
TORC1 Modulation Brings Aging Biology to Skincare
Rapalogix has secured $20 million in Series A funding to commercialize Re-Q, a skincare line targeting TORC1 signaling—a cellular pathway central to aging biology. The investment reflects longevity biotech's shift toward tractable, measurable clinical endpoints and near-term commercial viability rather than abstract lifespan claims.
Dual agonist reverses liver fibrosis and cardiometabolic dysfunction
Pemvidutide, a dual glucagon/GLP-1 receptor agonist, demonstrated sustained reductions in cardiometabolic risk factors and liver fibrosis over 48 weeks in patients with metabolic dysfunction-associated steatohepatitis. This positions the compound as a potential therapeutic option in a therapeutic area where metabolic and hepatic dysfunction often progress in parallel.
Omada Health study boosts quality of GLP-1 weight loss
A 12-week study of GLP-1 users receiving structured digital support achieved 1.8 times greater total weight loss, with twice the fat loss and nearly threefold greater muscle preservation compared to medication alone. The research demonstrates that weight loss quality—measured by body composition and functional outcomes—is a more meaningful indicator of health benefit than weight reduction alone.
Oral GLP-1 Manufacturing Breakthrough Addresses Supply Constraints
The MHRA has approved orforglipron (Foundayo), an oral GLP-1 receptor agonist tablet, ahead of regulatory decisions in the EU and US. The approval addresses a critical manufacturing constraint that has limited supply of injectable GLP-1s, but NHS access remains contingent on a separate NICE cost-effectiveness review.
GLP-1 joint injection shows promise for knee osteoarthritis
4Moving Biotech has enrolled 129 patients in a Phase 2a trial of 4P004, a GLP-1 receptor agonist delivered directly into the knee joint to reduce inflammatory mechanisms in osteoarthritis. The trial will measure pain reduction and synovial tissue changes over 12 weeks, with results expected by end of 2026.
Blood-brain delivery reshapes GLP-1 neuroprotection strategy
GLP-1 receptor agonists show potential neuroprotective effects, but first-generation drugs failed to achieve sufficient brain penetration. A new partnership between Kariya Pharmaceuticals and NeuraLight is testing KP405, a blood-brain barrier-penetrating GLP-1 analog engineered specifically for neurodegenerative disease, paired with AI-driven biomarkers to detect cognitive protection earlier than traditional clinical endpoints.
Intermittent chloroquine extends lifespan by enhancing cellular clearance
Intermittent chloroquine treatment extended lifespan in female rats while preventing mammary hyperplasia and reducing circulating LDL and IGFBP3—markers associated with metabolic dysfunction and tissue overgrowth. This intervention operates through cellular clearance mechanisms, suggesting a pathway distinct from standard pharmaceutical approaches to longevity.
Transdermal GLP-1 Patch Eliminates Weekly Injection Burden
Anodyne Nanotech secured $12.6 million in Series A funding to advance ANN-101, a once-weekly transdermal GLP-1 patch designed for obesity management. The solid-state microneedle platform eliminates injection requirements and cold-chain dependency while maintaining pharmacological equivalence to injectable therapies, addressing adherence barriers in weight management protocols.
Muscle preservation emerges as critical GLP-1 treatment frontier
NorthStrive Biosciences has filed patent applications for two distinct muscle-preservation technologies—a peptide (EL-22) and an engineered microorganism platform (EL-32)—designed to mitigate lean mass loss during GLP-1 and multi-hormone weight-loss treatment. This represents a shift in obesity medicine from maximizing weight loss alone to preserving metabolic and structural integrity during pharmacological intervention.
NADMED backs Cleveland Clinic transplant study
Cleveland Clinic's awarded research uses redox biology—specifically NAD and NADH measurement—to assess metabolic viability of donor organs during the ischemic period before transplantation. This work translates longevity science concepts into actionable clinical tools for organ quality assessment and transplant outcomes.
TORC1 inhibition advances skin longevity beyond cosmetic treatment
Rapalogix Health secured $20 million in Series A funding to expand its skincare line targeting TORC1, a cellular pathway implicated in skin aging. The company's approach addresses how cells regulate nutrient sensing and protein synthesis—processes that deteriorate with age and manifest visibly in skin structure and appearance.
Novo’s triple-G obesity drug hits 19.7% loss in China trial
A triple-agonist obesity drug (UBT251) achieved 19.7% weight loss over 24 weeks in a Phase 2 trial, with concurrent improvements in glucose, blood pressure, and lipid profiles. This represents a shift toward multi-system metabolic intervention rather than single-pathway hormone modulation, with implications for reducing chronic disease burden across the lifespan.
Dual-Pathway Pemvidutide Shows Sustained Metabolic Repair in MASH
Pemvidutide, an investigational dual-pathway therapy, demonstrates sustained metabolic improvements across liver function, lipid profiles, and cardiovascular risk markers in a 48-week Phase 2b trial. The data suggest a mechanistic advantage over single-pathway GLP-1 agents by addressing the interconnected metabolic dysfunction underlying fatty liver disease and cardiovascular risk.
NB4168 bioavailability edge for rare disease clinical trials
Niagen Bioscience is advancing NB4168, an oral candidate for Ataxia Telangiectasia, through preclinical development with contract partner Evotec. Nonclinical studies show NB4168 achieves substantially higher blood exposure than NR chloride, positioning the compound for IND submission and clinical evaluation.
Magnesium Deficiency Accelerates Gut Aging and Increases Susceptibility to Colitis
Magnesium deficiency accelerates intestinal aging and increases susceptibility to colitis by destabilizing cellular adhesion complexes. Population data from 182,213 individuals shows dietary magnesium intake of 334.7–420.0 mg/day significantly reduces risk of inflammatory bowel disease, irritable bowel syndrome, and related disorders.
Oral Obesity Drugs Eliminate Injection Barrier in Metabolic Care
Rani Therapeutics partnered with PegBio to develop oral formulations of obesity and metabolic disease therapies using its RaniPill platform, addressing a critical barrier to long-term treatment adherence. The collaboration evaluates multiple drug candidates with different mechanisms of action, reflecting the field's shift beyond single-pathway GLP-1 therapies toward personalized metabolic intervention.
GLP-1 Agonist Advances to Phase 3: Oral Route Targets Adherence
Kailera Therapeutics advanced its obesity therapeutic pipeline with a fully enrolled Phase 2b ribupatide injection trial and initiated planning for global Phase 3 studies of an oral formulation, with data readouts expected through 2028. The company maintains sufficient funding to support operations into mid-2028, positioning it to deliver clinical evidence on a GLP-1 receptor agonist candidate in a therapeutic area central to metabolic and cardiovascular health.
One-time gene therapy targets metabolic reset
Fractyl Health has received regulatory approval to initiate Phase 1/2 trials of RJVA-001, a single-administration gene therapy designed to enable patients' own cells to produce GLP-1 indefinitely. This represents a shift toward durable metabolic interventions that require one-time dosing rather than ongoing pharmaceutical management.